Skandinaviska Enskilda Banken AB publ Boosts Stock Holdings in Johnson & Johnson $JNJ

Skandinaviska Enskilda Banken AB publ lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 6.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 764,884 shares of the company’s stock after buying an additional 48,557 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s holdings in Johnson & Johnson were worth $141,825,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. denkapparat Operations GmbH raised its stake in shares of Johnson & Johnson by 5.1% during the 3rd quarter. denkapparat Operations GmbH now owns 5,334 shares of the company’s stock valued at $989,000 after purchasing an additional 260 shares during the period. SMART Wealth LLC increased its position in shares of Johnson & Johnson by 18.5% during the third quarter. SMART Wealth LLC now owns 1,926 shares of the company’s stock valued at $357,000 after buying an additional 300 shares during the period. Southeast Asset Advisors LLC increased its position in shares of Johnson & Johnson by 14.7% during the third quarter. Southeast Asset Advisors LLC now owns 48,154 shares of the company’s stock valued at $8,929,000 after buying an additional 6,167 shares during the period. Summitry LLC boosted its position in shares of Johnson & Johnson by 8.2% in the third quarter. Summitry LLC now owns 51,003 shares of the company’s stock valued at $9,457,000 after acquiring an additional 3,853 shares during the period. Finally, Zions Bancorporation National Association UT boosted its position in shares of Johnson & Johnson by 9.3% in the third quarter. Zions Bancorporation National Association UT now owns 59,630 shares of the company’s stock valued at $11,057,000 after acquiring an additional 5,094 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Down 0.5%

Shares of JNJ stock opened at $243.37 on Tuesday. The business has a 50-day moving average price of $218.09 and a two-hundred day moving average price of $197.35. Johnson & Johnson has a 12-month low of $141.50 and a 12-month high of $246.35. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.48. The firm has a market cap of $586.51 billion, a P/E ratio of 22.02, a price-to-earnings-growth ratio of 2.36 and a beta of 0.35.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. The company had revenue of $24.28 billion for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%. Equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.1%. Johnson & Johnson’s dividend payout ratio is 47.06%.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several recent analyst reports. HSBC increased their target price on shares of Johnson & Johnson from $240.00 to $265.00 and gave the stock a “buy” rating in a research note on Friday, January 30th. Leerink Partners increased their price objective on Johnson & Johnson from $201.00 to $232.00 and gave the stock a “market perform” rating in a research report on Thursday, January 22nd. Weiss Ratings reissued a “buy (b)” rating on shares of Johnson & Johnson in a research note on Wednesday, January 28th. Johnson Rice set a $190.00 target price on Johnson & Johnson and gave the stock a “hold” rating in a research note on Wednesday, October 22nd. Finally, Royal Bank Of Canada lifted their price target on Johnson & Johnson from $240.00 to $255.00 and gave the company an “outperform” rating in a research report on Tuesday, February 3rd. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and an average price target of $233.73.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.